Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Warren Olanow

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
The Lancet. Neurology|April 13, 2011
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomesOlivier Rascol, Cheryl J Fitzer-Attas, Robert Hauser, et al.
Annals of Neurology|September 4, 2003
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's diseaseC Warren Olanow, Christopher G Goetz, Jeffrey H Kordower, et al.
Annals of Neurology|December 1, 2016
Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patientJeffrey H Kordower, Christopher G Goetz, Yaping Chu, et al.
The Lancet. Neurology|April 5, 2008
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trialWilliam J Marks, Jill L Ostrem, Leonard Verhagen, et al.
Journal of Parkinson'S Disease|January 22, 2024
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's DiseaseMilton H Werner, C Warren Olanow, Andrew McGarry, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 14, 2011
Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's diseaseAndrew Lees, Stanley Fahn, Karla M Eggert, et al.
Sleep Medicine|November 1, 2003
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonistsThomas Roth, David B Rye, Leona D Borchert, et al.
The Lancet. Neurology|December 24, 2013
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyC Warren Olanow, Karl Kieburtz, Per Odin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's diseaseC Warren Olanow, Karl Kieburtz, Mika Leinonen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 13, 2014
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's diseaseDaniela Berg, Ronald B Postuma, Bastiaan Bloem, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
The Lancet. Neurology|April 13, 2011
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomesOlivier Rascol, Cheryl J Fitzer-Attas, Robert Hauser, et al.
Annals of Neurology|September 4, 2003
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's diseaseC Warren Olanow, Christopher G Goetz, Jeffrey H Kordower, et al.
Annals of Neurology|December 1, 2016
Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patientJeffrey H Kordower, Christopher G Goetz, Yaping Chu, et al.
The Lancet. Neurology|April 5, 2008
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trialWilliam J Marks, Jill L Ostrem, Leonard Verhagen, et al.
Journal of Parkinson'S Disease|January 22, 2024
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's DiseaseMilton H Werner, C Warren Olanow, Andrew McGarry, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 14, 2011
Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's diseaseAndrew Lees, Stanley Fahn, Karla M Eggert, et al.
Sleep Medicine|November 1, 2003
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonistsThomas Roth, David B Rye, Leona D Borchert, et al.
The Lancet. Neurology|December 24, 2013
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyC Warren Olanow, Karl Kieburtz, Per Odin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's diseaseC Warren Olanow, Karl Kieburtz, Mika Leinonen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 13, 2014
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's diseaseDaniela Berg, Ronald B Postuma, Bastiaan Bloem, et al.
Pageof 15